Background Newer-generation amide local anesthetic drugs are relatively less cardiotoxic and neurotoxic than bupivacaine and thus can be used as safer alternatives to reduce bupivacaine-related toxicity. In the present study, we hypothesized that isobaric 0.5% levobupivacaine would be more efficacious than 0.75% ropivacaine in terms of the onset and duration of sensory and motor block, hemodynamic effects, and duration of analgesia. Methods Ninety patients who met the inclusion criteria were enrolled and randomly assigned to one of two groups. Patients in Group L received 3 mL of 0.5% levobupivacaine (n = 45), and those in Group R received 3 mL of 0.75% ropivacaine (n = 44). Evaluations were performed at different time intervals to assess sensory and motor block, hemodynamic parameters, analgesic effectiveness, duration of analgesia, side effects, Visual Analog Scale score, and the need for rescue analgesia. Results Patients in Group L experienced a faster onset of sensory block (5.9 minutes) and motor block (8.6 minutes) than patients in Group R, who had a sensory block onset of 8.3 minutes and a motor block onset of 11.7 minutes. The duration of sensory block was longer in Group L, with a mean duration of 268 minutes, compared with Group R, which had a mean duration of 160 minutes. The duration of motor block was also longer in Group L (230 minutes) than in Group R (136 minutes) (p < 0.0001). Conclusions Both ropivacaine and levobupivacaine provided adequate subarachnoid block for infraumbilical surgeries. However, levobupivacaine provided more effective anesthesia, with a faster onset, longer duration of sensory and motor block, and prolonged postoperative analgesia compared with ropivacaine. The prolonged sensory block with levobupivacaine resulted in less postoperative pain and reduced the need for early rescue analgesia, but at the cost of prolonged motor blockade. Both drugs are more cardiostable than bupivacaine and can be used safely as alternatives to bupivacaine.

This study evaluated the pharmacokinetic profiles and comparative bioavailability of etoricoxib 90 mg tablets and betamethasone 0.25 mg/0.5 mL solution, administered individually (reference drugs), versus a fixed-dose combination (FDC) tablet containing etoricoxib 90 mg and betamethasone 0.25 mg (test drug) under fasting conditions in healthy Mexican volunteers. A randomized, open-label, three-period, crossover, single-dose study with a 14-day washout period was conducted. Study drugs were administered orally following a 10-h overnight fast with 250 mL of water and fasting continued for at least 4 h post-dose. Serial blood samples were collected pre- and post-dose, and the drug concentrations were quantified using Liquid Chromatography coupled to Tandem Mass Spectrometry (LC-MS/MS). Forty-two subjects (22 women, 20 men; mean age 22.7 years; mean weight 64.7 kg) were enrolled, and 39 completed the study. Comparative bioavailability was established if the 90% confidence intervals of log-transformed Cmax and AUC0-72 h fell within the predefined range of 80%-125%. Two non-serious adverse events were reported. Results demonstrated that the pharmacokinetic profile and bioavailability of the etoricoxib/betamethasone FDC were comparable to those of reference formulations, with no evidence of pharmacokinetic interactions.

This study investigates the therapeutic potential of compounds derived from natural products as anti-inflammatory and analgesic agents. It focuses on their ability to modulate the P2X7 receptor, a key protein involved in purinergic signaling that plays a crucial role in the inflammatory response and pain transmission. The goal is to identify promising candidates for developing new treatments for chronic inflammation, neuropathic pain, and cancer, highlighting the relevance of natural sources for safer, sustainable therapies. These compounds could serve as prototypes for new anti-inflammatory and analgesic drugs, including P2X7 receptor antagonists. A search of databases, including PubMed and Google Scholar, was performed to identify relevant studies published since 2017. Search terms included "P2X7 receptor", "natural products", "inflammatory diseases" and "neuropathic pain". Additional articles were identified through manual searching of reference lists. The review identified 35 studies exploring the effects of natural products on purinergic signaling, targeting the P2X7 receptor. These studies highlighted 24 plant species and 36 compounds for their anti-inflammatory and analgesic properties, focusing on P2X7 receptor modulation. Significant findings included inhibition of inflammatory mediators and pain relief, measured by IC50 values. This review concludes that these natural products are promising for developing new anti-inflammatory agents, given their inhibition of inflammatory mediators and the P2X7 receptor. The diverse activities of these phytochemicals offer potential treatments for chronic diseases associated with inflammation and pain. Further research on mechanistic actions and clinical efficacy is necessary to validate their therapeutic potential and develop effective phytotherapeutics.

The initiation of cancer is accompanied by a large number of epigenetic changes, underscoring their crucial role in cancer initiation, progression, and metastasis, as well as the development of resistance to therapies (most recently, the formation of drug-resistant oncogenic cell lines). Epigenetic modifications are capable of being reversed, thus making them attractive targets for pharmacological intervention. A large number of agents are available for use that are primarily recognized as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which primarily provide anti-inflammatory and analgesic benefit. However, this class of agents has also been identified as having the potential to modulate epigenetic mechanisms and consequently exert chemopreventive and anticancer properties. Although the principal mechanism of action of NSAIDs is via the inhibition of the Cyclooxygenase (COX) pathway(s), thus resulting in a decrease in the enzyme activity of prostaglandin synthase, emerging evidence indicates that they also have effects on alternative signaling pathways that are considered COX-independent. This recent evidence indicates that NSAIDs also impact key epigenetic mechanisms such as the regulation of DNA Methyltransferase (DNMT) and Histone Deacetylase (HDAC) enzymes, which are responsible for regulating DNA methylation and histones, respectively, through Peroxisome Proliferator-Activated Receptors (PPARs). The impact of NSAIDs on both DNMT and HDAC enzymes contributes to the reactivation of tumor suppressor genes and the reversal of oncogene activity, inhibition of cell division, and promotion of apoptosis. The efficacy and toxicity of NSAIDs in the treatment of cancer depend on a number of factors, including the type of drug used, dosage, pharmacokinetics, and individual genetic or epigenetic background. This review will examine the emerging roles of NSAIDs as modulating agents for epigenetic mechanisms of action, including the mechanisms of action, pre-clinical and clinical evidence, and potential synergies with existing therapies that are designed to modulate epigenetic mechanisms.

Nonsteroidal anti-inflammatory drugs have been reported to enhance oral sensitization to food allergens, potentially through disruption of the intestinal epithelial barrier. Epithelial-derived cytokines, including thymic stromal lymphopoietin (TSLP), interleukin (IL)-33, and IL-25, promote immunoglobulin E (IgE) production by inducing T helper type 2 immune responses and may contribute to allergen sensitization following epithelial injury. This study aimed to investigate oral sensitization to ovalbumin (OVA) in a rat model of intestinal epithelial injury induced by dextran sulfate sodium (DSS) or indomethacin (IND), focusing on the involvement of TSLP in relation to the anatomical site of epithelial injury. Rats were orally immunized with OVA by gavage every other day for 6 weeks. DSS was administered in drinking water from 2 weeks before immunization, whereas IND was administered orally at a dose of 6 mg/kg 30 min before each OVA administration. To explore the involvement of TSLP, anti-TSLP antibodies were administered intraperitoneally once a week throughout the immunization period. Histological analysis showed that DSS induced epithelial injury in both the jejunum and proximal colon, whereas IND caused milder epithelial injury limited to the jejunum. Plasma OVA-specific IgE (OVA-sIgE) levels were elevated in both models. Anti-TSLP antibody treatment attenuated DSS-enhanced OVA-sIgE production, but had limited effects in the IND model. In conclusion, intestinal epithelial injury may enhance oral sensitization through mechanisms that differ according to the anatomical site and extent of injury. TSLP appears to contribute predominantly to sensitization associated with epithelial damage involving both the jejunum and proximal colon.

Neutrophils, key effector cells of the innate immune system, infiltrate infected tissues, adhere to them, and destroy pathogens by releasing the bactericidal content of intracellular granules and producing reactive oxygen species (ROS) and nitric oxide (NO). However, these aggressive antimicrobial products of neutrophil secretion can damage surrounding tissues and initiate inflammation. Adenosine, which is produced in excess by damaged tissues, is known to limit the neutrophil immune response and suppress inflammation, acting primarily through adenosine receptors. We compared the effects of ATP, adenosine, and iodoacetic acid (IAA), an inhibitor of glycolysis, on neutrophil adhesion to fibronectin and accompanying secretion of free amino acids, proteins, ROS, and NO. Our results indicate that the immunosuppressive effect of adenosine is unlikely to be due to the inhibition of oxidative stress or protein secretion. Neither ATP nor adenosine altered ROS and NO production during neutrophil adhesion, whereas IAA suppressed it. ATP did not affect the composition of secreted proteins, while adenosine stimulated the release of aggressive components of primary granules. We also investigated previously undescribed dynamics of secretion of the amino acid hydroxylysine by neutrophils during adhesion: ATP stimulated, while adenosine and IAA selectively and strongly inhibited hydroxylysine release. Hydroxylysine is a product of lysyl hydroxylase (LH), whose expression and activity positively correlate with cell invasiveness and metastatic potential of various types of tumor cells. Given the similarities between neutrophils and tumor cells in energy metabolism and invasive capacity, we hypothesize that adenosine and IAA may suppress immune responses by inhibiting neutrophil infiltration into tissues through selective blocking of LH activity/hydroxylysine release. Further studies are required to directly test this hypothesis.